2-[(E)-(2,4,6-trimethoxyphenyl)methylideneamino]guanidine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-[(E)-(2,4,6-trimethoxyphenyl)methylideneamino]guanidine
• 化学式: C₁₁H₁₆N₄O₃
• 分子量: 252.27
• InChiKey: OJKUNYWKLHFXDQ-MKMNVTDBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• [EN] GUANIDINE DERIVATIVES AND THEIR USE IN THE PRODUCTION OF A MEDICAMENT FOR BLOCKING XANTHINE OXIDASE/DEHYDROGENASE<br/>[FR] DERIVES DE GUANIDINE ET LEUR UTILISATION DANS LA PRODUCTION D'UN MEDICAMENT DESTINE A BLOQUER LES XANTHINE OXYDASES/DESHYDROGENASES
  申请人：MELACURE THERAPEUTICS AB

  公开号：WO2001025192A1

  公开（公告）日：2001-04-12

  The present invention relates to guanidine derivatives and pharmaceutically acceptable acid salts thereof. The invention further relates to pharmaceutical preparations containing said compounds, and the use of said compounds for treatment of any type of condition where the expression of xanthine oxidase/xanthine dehydrogenase enzymes is involved. The invention particularly relates to the use of these compounds in the preparation of a medicament for enhancing the survical of a transplanted cell, organ or tissue, or cell, organ or tissue to be transplanted.

  本发明涉及胍衍生物及其药用酸盐。本发明还涉及含有该化合物的制药制剂，以及使用该化合物治疗涉及黄嘌呤氧化酶/黄嘌呤脱氢酶酶表达的任何类型疾病的用途。本发明特别涉及使用这些化合物制备增强移植细胞、器官或组织的存活或待移植的细胞、器官或组织的药物。
• NEUROLOGICALLY ACTIVE COMPOUNDS AND COMPOUNDS WITH MULTIPLE ACTIVITIES
  申请人：Naftchi Eric N.

  公开号：US20070082918A1

  公开（公告）日：2007-04-12

  Pharmacologically active compounds suitable for treating a mammal so as to affect neurological function, the compounds comprising at least two neurologically active groups, one group providing alpha-adrenergic agonist activity, and the second group providing agonist activity selected from the group consisting of beta-adrenergic agonist activity, serotinergic agonist activity, dopaminergic agonist activity, and GABA-ergic agonist activity. Each of the compounds being lipophilic, capable of crossing the blood/central nervous system barrier and effective as the primary therapeutic agent, in a dosage amount and at a dosage rate sufficient to provide the desired effect. Therapeutic compositions comprising the compound are provided.

  具有药理活性的化合物，适用于治疗哺乳动物以影响神经功能，该化合物包括至少两个神经活性基团，其中一个基团提供α-肾上腺素能激动剂活性，第二个基团提供从以下组中选择的激动剂活性：β-肾上腺素能激动剂活性、血清素能激动剂活性、多巴胺能激动剂活性和GABA-能激动剂活性。每种化合物都是亲脂性的，能够穿过血液/中枢神经系统屏障，并且在剂量和剂量速率足以提供所需效果的情况下作为主要治疗剂有效。提供了包含该化合物的治疗组合物。
• Self-assembled active agents
  申请人：The United States of America, as represented by the Secretary of Agriculture

  公开号：US11166464B2

  公开（公告）日：2021-11-09

  A self-assembled active agent may be formed by a process including covalently bonding at least a first component molecule and a second component molecule, the two component molecules displaying synergy such that the effective amount of the self-assembled active agent is lower than the sum of the effective amounts of the first component molecule and the second component molecule. The component molecules may be chosen such that the covalent bonding is reversible, for example through a hydrazone bond between an amine and an aldehyde. The active agent may thus have controllable activity such as an antimicrobial agent, a biocide, an antiviral agent, a preservative, an antifouling agent, a disinfectant, or a sensor agent, such as for a particular molecule or for pH.

  自组装活性剂可通过一种工艺形成，该工艺包括至少共价键合第一组分分子和第二组分分子，这两种组分分子显示出协同作用，从而使自组装活性剂的有效量低于第一组分分子和第二组分分子的有效量之和。可以选择共价键可逆的组分分子，例如通过胺和醛之间的腙键。因此，活性剂可具有可控活性，如抗菌剂、杀菌剂、抗病毒剂、防腐剂、防污剂、消毒剂或传感剂，如针对特定分子或 pH 值的传感剂。
• US6413962B1
  申请人：——

  公开号：US6413962B1

  公开（公告）日：2002-07-02